(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(1.06%) $79.21
(-1.09%) $2.18
(-0.34%) $2 316.20
(0.08%) $27.57
(-0.22%) $986.20
(0.12%) $0.931
(0.06%) $10.91
(0.12%) $0.800
(0.19%) $91.61
Live Chart Being Loaded With Signals
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 566 171 |
Vidutinė apimtis | 544 684 |
Rinkos kapitalizacija | 14.23B |
EPS | CNY0 ( 2024-04-28 ) |
Kita pelno data | ( CNY0 ) 2024-05-29 |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | 37.87 |
ATR14 | CNY0.0950 (0.10%) |
Tūris Koreliacija
Shanghai Haohai Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Shanghai Haohai Koreliacija - Valiuta/Žaliavos
Shanghai Haohai Finansinės ataskaitos
Annual | 2023 |
Pajamos: | CNY2.63B |
Bruto pelnas: | CNY1.85B (70.34 %) |
EPS: | CNY2.44 |
FY | 2023 |
Pajamos: | CNY2.63B |
Bruto pelnas: | CNY1.85B (70.34 %) |
EPS: | CNY2.44 |
FY | 2023 |
Pajamos: | CNY0 |
Bruto pelnas: | CNY0 (0.00 %) |
EPS: | CNY0 |
FY | 2022 |
Pajamos: | CNY2.10B |
Bruto pelnas: | CNY1.45B (68.79 %) |
EPS: | CNY1.040 |
Financial Reports:
No articles found.
Shanghai Haohai
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.